GLOW blend: what it contains and what is known
In short
GLOW is a peptide blend sold online that sellers say contains GHK-Cu, BPC-157 and TB-500. We know of no published study of the product itself.
- The composition sellers declare is usually GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg in a 70 mg vial. The content has not been tested by an independent laboratory, and a seller's declaration does not guarantee it [10]E, not peer-reviewed.
- These components have mainly animal and laboratory studies, and human studies of GHK-Cu mostly concern skin creams [3, 4].
- In rats, the combination of BPC-157 and TB-500 gave no added benefit over either one alone [2]C.
- Fimea warns against injectable peptides bought online, and all three declared substances are named in the Finnish medicines list [1, 8]regulator.
What is the GLOW blend?
The GLOW blend’s composition rests on sellers’ declarations. The content has not been tested by an independent laboratory [10]E, not peer-reviewed.
GLOW is the name of a peptide blend sold online. On the product pages of nine sellers (13 Oct 2026) all declared the same three components and the same split in the 70 mg vial. One seller also listed a 50 mg vial declared to hold 35 mg GHK-Cu, 5 mg BPC-157 and 10 mg TB-500 [10]E, not peer-reviewed. Sellers are not named or linked.
The components sellers declare are these three:
- BPC-157 is a synthetic peptide of 15 amino acids, originally isolated from gastric juice [3].
- TB-500 is, according to the FDA, a fragment of thymosin beta-4 [7]regulator.
- GHK-Cu is the copper complex of the human three-amino-acid peptide GHK [4].
Fimea gives BPC-157 and TB-500 as example names under which peptide products are sold online [1]regulator. Blends in general: Peptide blends: what is in the vial and why the seller's label is not enough. All blends: Blends.
Evidence at a glance
Each cell gives the kind of study and its source. The letter is the evidence level, not the result. Rows on single components do not concern the GLOW product.
| Claimed effect | Humans | Animals | Cells |
|---|---|---|---|
| The GLOW blend itself | None known to us | None known to us | - |
| BPC-157 and TB-500 together | - | In rats no added benefit over either alone [2]C | - |
| BPC-157 (declared component) | Three small pilot studies [3] | Tissue repair in animal models [3]C | - |
| TB-500 (declared component) | No human exposure data [7]regulator | In rats the repaired tendon withstood a higher load [2]C | - |
| GHK-Cu (declared component) | Small facial cream studies, not injections [4] | Tissue renewal in animal studies [4]C | Collagen production in the laboratory [5]D |
| Safety | No data on the blend; little human data on unapproved peptides [6] | - | - |
"-" = no study on this.
Has the GLOW blend been studied?
Not as far as we know (see In short above). We know of the three-substance combination only from general reviews.
What is known about the single components
The results below concern single components, not the GLOW product.
- BPC-157 and TB-500 together. In a rat study, the repaired Achilles tendons of 32 rats were treated for four weeks with BPC-157, TB-500, their combination or nothing. In the TB-500 group the tendon withstood a higher load than in controls. The combination gave no added benefit over either one alone [2]C. GHK-Cu was not included.
- BPC-157. According to a review, BPC-157 has affected tissue repair in animal models, but only three small pilot studies have been published in humans [3].
- GHK-Cu. According to a review, GHK-Cu has more than four decades of laboratory and animal studies, but randomised human trials are small and mostly concern facial creams [4]. Skin cream results do not tell what happens if the substance is injected.
- In general. According to a 2026 review, many unapproved peptides have favourable results in animal models, but reliable human safety data are scarce [6].
Evidence on single substances does not transfer to a blend. When the blend's actual content, amounts and purity have not been independently tested, nothing about its effects can be inferred from these studies.
Who studies the GLOW blend?
No one that we know of has published research on this product (see above).
Who wrote this page: the editorial team
This page was written by the Molecular Recovery editorial team. The draft was made with the help of AI, and the claims were checked against the sources (AI policy). The page has not been medically reviewed. How we work: About us.
What side effects can the GLOW blend have?
There are no data on the blend's harms, because the blend has not been studied. According to Fimea, there is no reliable information on the content, quality and safety of products sold as peptides [1]regulator.
What users report. In the Reddit accounts we compiled (not research), 44 of 70 people (63%) reported some harm, most often: injection site pain, redness or lump (27, 39%), fatigue (4, 6%), mood or anxiety (4, 6%) and sleep problems (4, 6%). People tend to post when something goes wrong, so this share does not tell how common harms are. The figures are about the GLOW blend as sold or as the writer named it, not about its single substances, and the blend's contents were not verified. 30 people (43%) used other substances at the same time. The harms in detail: GLOW blend user experiences.
Risks of the combination, based on the declared components
- The FDA says BPC-157 and injectable GHK-Cu may carry a risk of immune reactions. There are few human data on GHK-Cu, and for TB-500 the FDA has found no human exposure data at all [7]regulator.
- For GHK-Cu the FDA mentions a tendency to form aggregates [7]regulator.
- According to a review, unapproved peptides carry a possibility of serious harm, because human safety data are scarce [6].
- For injectable products, impurities such as endotoxins that end up in the product during manufacture raise the risk of serious health hazards [1]regulator.
The three-substance combination has not been studied for safety. When the content and amounts have not been independently tested, the risks of the combination cannot be assessed. More: Side effects and safety.
GLOW blend dosage in studies
There is no studied dose for the blend, and the ratio sellers declare has not been independently tested [10]E, not peer-reviewed. The only combination study was done in rats with injections into the abdominal cavity, and it is not a study of the GLOW product [2]C. Study doses of single substances: BPC-157 and TB-500. We found no human study of injected GHK-Cu doses. The blend itself has no dose page of its own.
Is the GLOW blend legal in Finland?
All three substances that sellers declare are named in the Finnish medicines list [8]regulator.
- Medicines list. In the Finnish medicines list (230/2025), BPC 157, TB-500 and GHK-Cu are named in annex 1 A, which covers medicinal substance analogues and prohormones classified as medicines [8]regulator.
- Fimea warning, 29 June 2026. Fimea warned about injectable peptides bought online, giving BPC-157 and TB-500 as examples. Fimea advises not ordering injectable peptides from online shops or through social media, and buying medicines only from legal pharmacies. A "for research use only" label means the product is not intended for humans [1]regulator.
- United States. BPC-157, TB-500 and injectable GHK-Cu were in FDA category 2, meaning bulk drug substances for compounding that may present significant safety risks. The nominators have since withdrawn the nominations, and the FDA page still shows the risk descriptions [7]regulator.
- Import. Peptides and the law. Bringing them back from travel: Travelling with peptides.
This is not legal advice. Disclaimer.
Is the GLOW blend doping?
Yes, if the vial holds what sellers declare. On the WADA 2026 Prohibited List, BPC-157 falls under class S0 (non-approved substances), and thymosin beta-4 and its derivatives, for example TB-500, under class S2. Both classes are prohibited at all times [9]regulator. In a blend, one prohibited component is enough.
How to assess a GLOW product
A seller's declared composition does not tell the buyer which substances are actually in the vial, how much of each, or whether something else is in it. According to Fimea, an unauthorised product may contain a different substance than the packaging states [1]regulator.
A certificate of analysis (COA) for a blend should identify each component separately by mass spectrometry (MS), state the amount of each, and refer to the same batch as the vial being sold. A COA that gives only one overall purity figure or just the blend name does not show the composition. For injectables, endotoxins are a particular risk [1]regulator. More: How to read a COA and check a test result.
FAQ
What does the GLOW blend contain?
The composition sellers declare is usually GHK-Cu, BPC-157 and TB-500, with 50 mg, 10 mg and 10 mg in a 70 mg vial. The content has not been tested by an independent laboratory, and a seller's declaration does not guarantee it [10].
Has the GLOW blend been studied?
Not as far as we know: we know of no published study of this product. The single components have mainly animal and laboratory studies [3, 4].
Is there human evidence for GHK-Cu?
Little. Human studies are small and mostly concern facial creams, not injections [4].
Is GLOW legal in Finland?
Fimea warns against injectable peptides bought online, and BPC 157, TB-500 and GHK-Cu are named in the medicines list [1, 8]regulator. The blend's actual content has not been independently tested. This is not legal advice.
What should a COA for a blend show?
Identity of each component by mass spectrometry, the amount of each, and the same batch as the vial. For an injectable, also an endotoxin result [1]regulator.
What do users themselves report about the GLOW blend?
In the Reddit accounts of 70 people we compiled (not research), 26 (37%) reported some benefit and 44 (63%) some harm. The accounts are self-selected and prove neither that it works nor that it is safe: GLOW blend user experiences.
Read the research yourself: sources
Every source opens the original publication or the regulator's page. The level shows what the source itself reports.
- Fimea. Fimea warns: do not use injectable peptides purchased online (29 Jun 2026). Fimea regulator
- Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37:822-837. PMID 42542926 C
- McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18:611-619. PMID 40789979 (review)
- Najafi N, et al. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9:269-293. PMID 42787770 (review)
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19. PMID 29986520 (review)
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56:1921-1935. PMID 41966639 (review)
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA regulator
- Finland. Lääkeluettelo (Fimea medicines list), 230/2025, annex 1 A. Finlex regulator
- World Anti-Doping Agency. 2026 Prohibited List. WADA regulator
- Seller product pages for GLOW, 9 sellers, read 13 Oct 2026: all 9 declare GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg in a 70 mg vial; one also lists a 50 mg vial (GHK-Cu 35 mg, BPC-157 5 mg, TB-500 10 mg). Sellers' own claims, not tested by an independent laboratory. Not linked: this site does not link to shops. E, not peer-reviewed
Study details checked in PubMed on 9 Oct 2026. Fimea, FDA, Finlex and WADA pages read on 15 Sep 2026. Seller product pages read on 13 Oct 2026; sellers are not named or linked.
Evidence levels: A = randomised human trial or meta-analysis · B = observational human study or case series · C = animal study · D = cell or laboratory study · E = not peer-reviewed · regulator = a regulator's assessment or decision, not research evidence. The marker official means official product information (summary of product characteristics or label); it is not research evidence. For a review, the level shows what kind of research the statement rests on. No level: statements that something has not been studied, reviews' interpretations, named hypotheses and the general rules in our certificate-of-analysis guide.
Content is general information about research, not medical advice. If you have symptoms, contact a healthcare professional.